Kite lines up a JV in China while Daiichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan
With its new drug application for the pioneering CAR-T drug KTE-C19 in the final weeks from being completed and shipped to regulators in search of an accelerated approval, Kite Pharma $KITE has now lined up two partners to manage their prospective leap into two key Asian markets. Kite has pulled the wraps off a joint venture for China while inking a $250 million-plus deal to break into the Japanese market alongside Daiichi Sankyo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.